|
WO1996024358A1
(en)
*
|
1995-02-10 |
1996-08-15 |
G.D. Searle & Co. |
Use of low dose amount of spironolactone for treatment of cardiovascular disease
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
FI20010233A0
(fi)
*
|
2001-02-08 |
2001-02-08 |
Orion Corp |
Menetelmä sydämen vajaatoiminnan hoitoon
|
|
FI20011464A0
(fi)
|
2001-07-04 |
2001-07-04 |
Orion Corp |
Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
|
|
US7020521B1
(en)
|
2002-11-08 |
2006-03-28 |
Pacesetter, Inc. |
Methods and apparatus for detecting and/or monitoring heart failure
|
|
JP2007511487A
(ja)
|
2003-11-17 |
2007-05-10 |
ノバルティス アクチエンゲゼルシャフト |
ジペプチジルペプチダーゼiv阻害剤の使用
|
|
US20060018970A1
(en)
*
|
2003-12-12 |
2006-01-26 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
(r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
|
|
EP1737448A1
(en)
*
|
2004-03-22 |
2007-01-03 |
Myogen, Inc. |
(s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
US20060292213A1
(en)
*
|
2004-06-23 |
2006-12-28 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of PDE-III mediated diseases
|
|
CN104644627A
(zh)
|
2004-09-14 |
2015-05-27 |
科罗拉多大学董事会 |
基于基因靶向使用布新洛尔的治疗方法
|
|
CA2610022A1
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
WO2007014029A2
(en)
*
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
|
|
WO2011032088A1
(en)
|
2009-09-11 |
2011-03-17 |
Arca Biopharma, Inc. |
Polymorphisms in the pde3a gene
|
|
CN110520116A
(zh)
*
|
2017-01-03 |
2019-11-29 |
卡尔迪奥克斯尔制药公司 |
供硝酰化合物的给予方法
|
|
EP4092013A1
(en)
|
2017-06-20 |
2022-11-23 |
Imbria Pharmaceuticals, Inc. |
Compositions and methods for increasing efficiency of cardiac metabolism
|
|
US12318382B2
(en)
|
2018-10-17 |
2025-06-03 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
EP3976101A4
(en)
|
2019-05-31 |
2023-06-21 |
Imbria Pharmaceuticals, Inc. |
FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
|
|
EP4146215A4
(en)
*
|
2020-05-04 |
2024-05-01 |
Imbria Pharmaceuticals, Inc. |
DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|